In a substantial boost for Canadian biotechnology, Aspect Biosystems has announced a $72.75 million investment from the Governments of Canada and British Columbia. This funding will underpin a $200 million, multi-year initiative aimed at enhancing the company's clinical biomanufacturing capabilities, as well as advancing its innovative tissue therapeutic platform and pipeline.

Aspect Biosystems is at the forefront of bioprinted tissue therapeutics, developing treatments designed to replace, repair, or supplement biological functions in the body. These next-generation therapeutics aim to provide new disease-modifying treatments and functional cures for some of the most challenging medical conditions.

The project will benefit from Aspect’s strategic partnership with global healthcare leader Novo Nordisk, which focuses on diabetes and obesity. It will also accelerate the company's own therapeutic pipeline addressing other serious metabolic and endocrine diseases, including liver disease.

“This significant investment from the Governments of Canada and B.C. signals strong support for building the capabilities needed to discover, develop, and clinically manufacture new medicines for people with serious diseases,” said Tamer Mohamed, Chief Executive Officer of Aspect Biosystems. “This is a major step forward in our mission to pioneer a new category of regenerative medicine and establish a globally leading biotech company that delivers sustainable, life-changing impacts to patients both domestically and internationally.”

The announcement was made at Aspect Biosystems’ Vancouver headquarters by the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, alongside the Honourable Brenda Bailey, Minister of Jobs, Economic Development and Innovation for British Columbia.

“Today’s investment in Aspect Biosystems strengthens Canada’s biotech sector, enhancing innovation and leadership in healthcare,” said François-Philippe Champagne. “It accelerates our transition from ideas to globally competitive products, bolsters our response to health emergencies, attracts international investments, and creates high-quality jobs for Canadians. British Columbia’s impressive talent pool further fuels our innovation in the next generation of medicines.”

“B.C. is home to the fastest growing life sciences sector in Canada and continues to garner global attention for the incredible work being done here,” added Brenda Bailey. “Supporting B.C.-based life sciences and biomanufacturing companies like Aspect helps anchor and grow our province’s capabilities, enhancing healthcare outcomes for British Columbians and creating hundreds of new, high-paying, skilled jobs.”

‍